What is PharmaFutures?

PharmaFutures is a multi-year, investor-led dialogue between the pharmaceutical industry and its investors about how to manage a rapidly-changing operating environment to deliver long-term value both to society and to shareholders. The project was initiated in 2004 as a scenario-planning exercise and has evolved to a more practically oriented, solutions-focused exploration of the link between sustainable pharmaceutical business models and global health outcomes.

The overarching objective of the initiative is to build trust and foster an environment in which collaborations and partnerships between industry and key stakeholders can flourish, leading to increased commercial opportunities and improved health outcomes.

Each of the PharmaFutures dialogues takes place in a Working Group comprised of asset owners, sell and buy-side analysts of the industry, senior pharmaceutical executives and global health experts. The Working Group’s deliberations are enriched by interviews with a diverse set of external experts. Meteos provides overall project direction and facilitation as well as research support.

  • PharmaFutures 1 a scenario-planning exercise, resulted in the report, PharmaFutures: A Long-Term Value Outlook, which outlines possible future scenarios for the industry.
  • PharmaFutures 2 analysed the key value drivers for the industry and society and published PharmaFutures 2: Prescription for Long-Term Value.
  • PharmaFutures 3 focused on identifying innovative, yet practical solutions – such as financing, partnerships and new business models – that will result in both commercial success and improved health outcomes in emerging markets, including India, China and Brazil. This work is reflected in the report PharmaFutures 3: Emerging Opportunities.
  • PharmaFutures 4: Shared Value, explores the growing challenge of reconciling unmet patient need with pharmaceutical R&D, in the context of changes in what society is willing to pay for and concerns among investors about the return on investment.
  • PharmaFutures 5: The latest PharaFutures dialogue explores the healthcare impact of long-term trends such as ageing, chronic diseases, risk and inequality in a radically changed economic context. It explores where these trends might lead and how healthcare innovation can be harnessed to improve productivity and efficiency.


The industry’s social contract is under severe strain. There is an urgent need for new treatments for antibiotics and diseases like Alzheimer’s. It is in the interest of patients, healthcare providers, industry and pension holders to work together to create the best model for bringing new drugs to market.

Sophia Tickell, Director, PharmaFutures